Nanobiotix S.A. ADR (NBTX)

Jan 21, 2025, 2:30 AM EST - 3 hours ago

NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer

Dec 17, 2024, 4:15 PM EST - 4 weeks ago

NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024

Dec 9, 2024, 4:15 PM EST - 6 weeks ago

NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer

Nov 12, 2024, 2:30 AM EST - 2 months ago

NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms

Oct 31, 2024, 3:30 AM EDT - 2 months ago

NANOBIOTIX to Participate in Multiple Investor Conferences in November

Sep 18, 2024, 4:15 PM EDT - 4 months ago

NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results

Sep 4, 2024, 4:15 PM EDT - 4 months ago

NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth

Sep 3, 2024, 4:15 PM EDT - 4 months ago

Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference

Jun 12, 2024, 4:15 PM EDT - 7 months ago

NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024

Jun 2, 2024, 10:00 AM EDT - 8 months ago

Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy

May 28, 2024, 4:15 PM EDT - 8 months ago

NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call

May 23, 2024, 4:15 PM EDT - 8 months ago

NANOBIOTIX to Present at the Jefferies Global Healthcare Conference

May 22, 2024, 8:32 PM EDT - 8 months ago

Nanobiotix S.A. (NBTX) Q1 2024 Earnings Call Transcript

May 22, 2024, 2:00 AM EDT - 8 months ago

NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update

May 21, 2024, 4:15 PM EDT - 8 months ago

Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth

May 15, 2024, 4:15 PM EDT - 8 months ago

NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024

May 14, 2024, 4:15 PM EDT - 8 months ago

NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer

Apr 27, 2024, 11:51 AM EDT - 9 months ago

Nanobiotix S.A. (NBTX) Q4 2023 Earnings Call Transcript

Apr 24, 2024, 4:40 PM EDT - 9 months ago

NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results

Apr 17, 2024, 4:15 PM EDT - 9 months ago

NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024

Apr 2, 2024, 4:15 PM EDT - 10 months ago

Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation

Mar 6, 2024, 4:15 PM EST - 11 months ago

Nanobiotix to Present at Upcoming Investor Conferences in March

Jan 31, 2024, 4:15 PM EST - 1 year ago

Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference

Jan 29, 2024, 4:15 PM EST - 1 year ago

Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study

Nov 14, 2023, 1:01 PM EST - 1 year ago

Nanobiotix S.A. (NBTX) Q3 2023 Earnings Call Transcript

Nov 13, 2023, 4:15 PM EST - 1 year ago

NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update

Nov 9, 2023, 4:15 PM EST - 1 year ago

NANOBIOTIX to Announce Third Quarter 2023 Operational and Financial Update on November 13, 2023

Nov 7, 2023, 4:01 PM EST - 1 year ago

NANOBIOTIX Announces Closing of Global Offering

Nov 6, 2023, 2:00 AM EST - 1 year ago

NANOBIOTIX Announces the Availability of a Prospectus in Connection with Capital Increases Raising Total Gross Proceeds of Approximately $50M and the Exercise by the Underwriters of the Over-Allotment Option for an Additional Amount of Approximately $3.6M

Nov 2, 2023, 10:49 AM EDT - 1 year ago

NANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55M

Nov 1, 2023, 6:32 PM EDT - 1 year ago

NANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash Covenant

Oct 23, 2023, 2:00 AM EDT - 1 year ago

NANOBIOTIX Announces Updated Preliminary Results From Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis From Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023

Oct 4, 2023, 4:30 PM EDT - 1 year ago

Nanobiotix Announces the Presentation of the Final Efficacy Analysis From Phase 1 Cohort Expansion Evaluating NBTXR3 in Locally Advanced Head and Neck Cancer Showing Median Progression-Free Survival of 16.9 Months and Median Overall Survival of 23.1 Month

Sep 29, 2023, 4:15 PM EDT - 1 year ago

NANOBIOTIX Announces Oral Presentation of Final Results From a Phase 1 Dose Expansion Study Evaluating NBTXR3 in Head and Neck Cancer at the 65th Annual Meeting of the American Society for Radiation Oncology

Sep 28, 2023, 4:15 PM EDT - 1 year ago

NANOBIOTIX Announces Presentation of First Data From Phase 1 Study Evaluating NBTXR3 for Patients With Locally Advanced Pancreatic Cancer

Sep 27, 2023, 10:52 AM EDT - 1 year ago

Nanobiotix S.A. (NBTX) Q2 2023 Earnings Call Transcript

Sep 26, 2023, 4:15 PM EDT - 1 year ago

NANOBIOTIX Provides Business Update and Financial Results for the First Half of 2023

Sep 19, 2023, 4:15 PM EDT - 1 year ago

Nanobiotix to Announce Half Year 2023 Financial Results on September 26, 2023

Sep 5, 2023, 4:15 PM EDT - 1 year ago

NANOBIOTIX Strengthens Global Development Capabilities With the Appointment of Veteran Industry Leader Dr. Louis Kayitalire as Chief Medical Officer

Aug 31, 2023, 4:15 PM EDT - 1 year ago

NANOBIOTIX to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 24, 2023, 8:40 AM EDT - 1 year ago

Nanobiotix: At A Crucial Juncture For Data

Aug 15, 2023, 4:15 PM EDT - 1 year ago

NANOBIOTIX Announces Expiration of HSR Waiting Period Regarding the Agreement for Worldwide Co-Development and Commercialization of Potential First-in-Class Radioenhancer NBTXR3

Aug 4, 2023, 4:15 PM EDT - 1 year ago

NANOBIOTIX to Host Extraordinary General Meeting of Shareholders on September 1st, 2023

Jul 19, 2023, 4:15 PM EDT - 1 year ago

NANOBIOTIX Announces First Patient Injected in New Phase 1/2 Study Evaluating Radiotherapy-Activated NBTXR3 Plus Anti-PD-1 for Patients With Advanced Cancers

Jul 10, 2023, 10:40 AM EDT - 1 year ago

Nanobiotix ADRs Jump Over 50% After Agreement With J&J's Janssen Pharmaceutical

JNJ

Jul 10, 2023, 6:14 AM EDT - 1 year ago

Nanobiotix's stock soars after entering licensing, development deal with J&J's Janssen Pharmaceutica

JNJ

Jul 10, 2023, 2:00 AM EDT - 1 year ago

NANOBIOTIX Announces License Agreement for Worldwide Co-development and Commercialization of Potential First-In-Class Radioenhancer NBTXR3

May 17, 2023, 4:15 PM EDT - 1 year ago

NANOBIOTIX Provides First Quarter 2023 Operational and Financial Update

May 5, 2023, 12:08 PM EDT - 1 year ago

Nanobiotix stock more than triples, after biotech enters final negotiations with ‘major' drug maker on development of cancer treatment

May 5, 2023, 1:30 AM EDT - 1 year ago

NANOBIOTIX Entering Final Contract Negotiations Following Agreement to Non-Binding Term Sheet for Development and Commercialization of NBTXR3 With a Major Global Pharmaceutical Company